Sun Pharmaceutical Industries Ltd. announced that US FDA has granted its subsidiary an approval for its New Drug Application (NDA) for Docefrez (docetaxel) for injection, 20 mg/vial and 80 mg/vial.
This NDA provides for the use of Docefrez (docetaxel) for injection, 20 mg/vial and 80 mg/vial for locally advanced or metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer and hormone refractory metastatic prostate cancer.